Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

Trial Identifier: D9106C00002
Sponsor: AstraZeneca
NCTID:: NCT05925530
Start Date: February 2024
Primary Completion Date: April 2026
Study Completion Date: August 2027
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AT Klagenfurt, AT, 9020
AT Wien, AT, 1140
AT Wien, AT, 1130
CA, BC Kelowna, BC, CA, V1Y 5L3
CA, ON Kingston, ON, CA, K7L 2V7
CA, QC Montreal, QC, CA, H4A 3J1
CA, Quebec Montreal, Quebec, CA, H2X 1R9
CZ Brno, CZ, 625 00
CZ Olomouc, CZ, 77900
CZ Prague, CZ, 12808
CZ Praha 5, CZ, 150 06
DE Berlin, DE, D-13353
DE Berlin, DE, 13125
DE Esslingen, DE, 73730
DE Gauting, DE, 82131
DE Grosshansdorf, DE, 22927
DE Köln, DE, 51109
DE Luebeck, DE, 23538
DE Moers, DE, 47441
DE München, DE, 81675
DE Offenbach am Main, DE, 63069
DE Wuerzburg, DE, 97074
ES Barakaldo, ES, 48903
ES Barcelona, ES, 08025
ES L'Hospitalet de Llobregat, ES, 08908
ES Madrid, ES, 28046
ES Madrid, ES, 28007
ES Madrid, ES, 28027
ES Valencia, ES, 46009
ES Zaragoza, ES, 50009
FR Brest Cedex, FR, 29609
FR La Tronche, FR, 38700
FR MARSEILLE, FR, 13008
FR Montpellier, FR, 34295
FR PARIS CEDEX 5, FR, 75005
FR POITIERS, FR, 86021
FR ROUEN, FR, 76031
FR Toulouse, FR, 31059
FR Vesoul, FR, 70000
HU Törökbálint, HU, 2045
IT Bari, IT, 70124
IT Bologna, IT, 40138
IT Milan, IT, 20141
IT Milano, IT, 20132
IT NAPOLI, IT, 80131
IT Palermo, IT, 90127
IT Pavia, IT, 27100
IT PESCHIERA DEL GARDA, IT, 37019
IT TREVISO, IT, 31100
PT Lisboa, PT, 1500-650
PT Lisboa, PT, 1350-352
PT Vila Nova De Gaia, PT, 4430-502
SE Lund, SE, 221 85
US, Florida Saint Petersburg, Florida, US, 33705
US, Illinois Chicago, Illinois, US, 60611
US, VA Charlottesville, VA, US, 22908